En Chang

No ORCID on file · 3 papers in corpus · active 2023-2024

Study types

  • meta-analysis 1
  • other 1
  • review 1

Condition tags

  • endometriosis 3
  • dysmenorrhea 2
  • chronic_pelvic_pain 1
  • dyspareunia 1
other 2024
Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
Expert opinion on drug safety ·doi:10.1080/14740338.2024.2351451

OBJECTIVE: Elagolix is approved for the treatment of moderate-to-severe pain associated with endometriosis. However, the long-term safety of elagolix in a large sample of real-world patients is unknown. METHODS: The U.S. Food and Drug Admi…

meta-analysis 2024
The short- and mid-term efficacy and safety of elagolix in the management of pain associated with endometriosis: A systematic review and meta-analysis
Journal of gynecology obstetrics and human reproduction ·doi:10.1016/j.jogoh.2024.102829

BACKGROUND: Elagolix, an approved non-peptide GnRH antagonist, shows promise in relieving endometriosis-related pain, but its short- and mid-term efficacy and potential side effects are still under investigation. OBJECTIVE: The aim is to p…

review 2023
Efcacy and safety of elagolix in moderate to severe endometriosis associated pain: a systematic review and meta analysis
·doi:10.37766/inplasy2023.9.0029

eview question / Objective The aim of this study is to comprehensively analyze evidence of elagolix in the treatment of moderateto-severe endometriosis-associated pain.Condition being studied Endometriosis-related pain, such as dysmenorrhea…